bioAffinity Technologies, Inc.
BIAF · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.07 | 0.02 | -0.03 | 0.20 |
| FCF Yield | -38.55% | -40.04% | -14.87% | -6.67% |
| EV / EBITDA | -1.73 | -2.06 | -4.19 | -14.65 |
| Quality | ||||
| ROIC | -100.99% | -95.13% | -71.82% | -40.83% |
| Gross Margin | 19.92% | 26.20% | 29.23% | 38.73% |
| Cash Conversion Ratio | 0.49 | 0.65 | 0.62 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | 176.24% | 582.56% | 1,054.62% | 1,149.25% |
| Free Cash Flow Growth | -57.20% | -0.92% | 2.41% | -10.12% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | -0.36 | -0.14 | -0.53 |
| Interest Coverage | -240.49 | -169.65 | -117.67 | -91.26 |
| Efficiency | ||||
| Inventory Turnover | 23.12 | 35.27 | 56.58 | 56.78 |
| Cash Conversion Cycle | -69.76 | -41.56 | -8.86 | 3.48 |